The National Cancer Institute (NCI)’s Antibody Characterization Program comprehensively characterizes monoclonal antibodies or other renewable affinity reagents for use in cancer related research via its Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR).
The ACL not only characterizes reagent specificity and performance, but also is in alignment with the National Institutes of Health’s Rigor and Reproducibility Principles and Guidelines.
The NCI’s antibody program seeks cancer related targets from the scientific community for affinity reagent production and characterization approximately every 12 to 18 months.
Selected antibodies undergo extensive characterization, with all data on the antibody portal.
Antibody Portal Stats
- 950 Antibodies
- 574 Antigen Targets
Central to reproducibility in biomedical research is being able to use well-characterized and defined reagents.
The CPTAC Antibody Portal serves as a National Cancer Institute (NCI) community resource that provides access to a large number of standardized renewable affinity reagents (to cancer-associated targets) and the accompanying characterization data for the reagents.